APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Study Intervention Participants Outcomes<br />
Core symptoms<br />
CPRS-R: impulsive-hyperactive<br />
Teacher Hyperactivity Index (ATR)<br />
ACTeRS: attention, hyperactivity<br />
Inclusion criteria<br />
1. Sexual maturity rating = 3 on Tanner’s scale.<br />
2. Long history <strong>of</strong> symptoms associated with attention deficit<br />
disorder<br />
3. Score = 15 on Abbreviated CTRS<br />
4. No mental retardation or gross neurological disorders<br />
Reference<br />
Brown <strong>and</strong> Sexton,<br />
1988 43<br />
Co-existent problems<br />
CPRS-R: conduct problems<br />
ACTeRS: oppositional behaviour, social skills,<br />
peer acceptance, dependence on <strong>and</strong><br />
solicitation from teacher<br />
Arm 1<br />
MPH<br />
0.15 mg/kg/dose administered twice<br />
daily (8 a.m., 12 p.m.); mean dose<br />
4.38 mg/dose<br />
(Administered by<br />
parent/teacher/clinic staff)<br />
Source<br />
CCOHTA Report<br />
Diagnostic criteria<br />
DSM-III<br />
Setting<br />
USA<br />
Arm 2<br />
MPH<br />
0.30 mg/kg/dose administered twice<br />
daily (8 a.m., 12 p.m.); mean dose<br />
12.55 mg/dose<br />
(Administered by<br />
parent/teacher/clinic staff)<br />
Design<br />
Crossover trial<br />
Educational performance<br />
CPRS-R: learning problems<br />
Arithmetic task: no. <strong>of</strong> questions attempted,<br />
no. <strong>of</strong> questions completed correctly,<br />
accuracy score, time spent<br />
Number<br />
Total r<strong>and</strong>omised = 11 (male = 11)<br />
No withdrawals reported<br />
Duration<br />
Total treatment period:<br />
8 weeks (2 weeks per<br />
treatment arm)<br />
Psychological function<br />
MFFT<br />
Gordon Diagnostic System (GDS)<br />
Depression or anxiety<br />
CPRS-R: anxiety<br />
Age<br />
13 years 7 months (mean);<br />
12 years 10 months – 14 years 10 months (range)<br />
IQ<br />
92.91 (mean)<br />
Co-morbid disorders<br />
Conduct disorder, socialised aggressive: 5/11 (DSM-III)<br />
Arm 3<br />
MPH<br />
0.50 mg/kg/dose administered twice<br />
daily (8 a.m., 12 p.m.); mean dose<br />
21.28 mg/dose<br />
(Administered by<br />
parent/teacher/clinic staff)<br />
© Queen’s Printer <strong>and</strong> Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
Quality <strong>of</strong> life<br />
Not reported<br />
Diagnostic subtypes<br />
Not reported<br />
Health Technology Assessment 2006; Vol. 10: No. 23<br />
Adverse events<br />
SERS: (parents)<br />
Additional information<br />
Previous medication: none <strong>of</strong> <strong>the</strong> participants had been treated<br />
with stimulants in <strong>the</strong> preceding year<br />
Additional outcomes<br />
Cardiovascular measures<br />
Weight<br />
Arm 4<br />
Placebo<br />
Administered twice daily (8 a.m.,<br />
12 p.m.)<br />
(Administered by<br />
parent/teacher/clinic staff)<br />
Purpose<br />
1. To examine <strong>the</strong><br />
efficacy <strong>of</strong> MPH,<br />
with ADD-H black<br />
adolescents<br />
2. To examine<br />
differential responses<br />
on laboratory <strong>and</strong><br />
behavioural measures<br />
according to varying<br />
dosages<br />
3. To examine sideeffects<br />
according to<br />
varying dosages<br />
4. To examine <strong>the</strong> effect<br />
<strong>of</strong> MPH on academic<br />
performance<br />
223